IL189628A0 - An anti-ca6 monoclonal antibody and a ca6 antigen specific cytotoxic conjugate containing the same - Google Patents

An anti-ca6 monoclonal antibody and a ca6 antigen specific cytotoxic conjugate containing the same

Info

Publication number
IL189628A0
IL189628A0 IL189628A IL18962808A IL189628A0 IL 189628 A0 IL189628 A0 IL 189628A0 IL 189628 A IL189628 A IL 189628A IL 18962808 A IL18962808 A IL 18962808A IL 189628 A0 IL189628 A0 IL 189628A0
Authority
IL
Israel
Prior art keywords
same
monoclonal antibody
antigen specific
specific cytotoxic
conjugate containing
Prior art date
Application number
IL189628A
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of IL189628A0 publication Critical patent/IL189628A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL189628A 2005-08-22 2008-02-20 An anti-ca6 monoclonal antibody and a ca6 antigen specific cytotoxic conjugate containing the same IL189628A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/030115 WO2007024222A1 (en) 2005-08-22 2005-08-22 A ca6 antigen-specific cytotoxic conjugate and methods of using the same

Publications (1)

Publication Number Publication Date
IL189628A0 true IL189628A0 (en) 2008-06-05

Family

ID=37771883

Family Applications (2)

Application Number Title Priority Date Filing Date
IL189628A IL189628A0 (en) 2005-08-22 2008-02-20 An anti-ca6 monoclonal antibody and a ca6 antigen specific cytotoxic conjugate containing the same
IL238798A IL238798A0 (en) 2005-08-22 2015-05-13 A ca6 antigen specific cytotoxic conjugate and methods of usinng the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL238798A IL238798A0 (en) 2005-08-22 2015-05-13 A ca6 antigen specific cytotoxic conjugate and methods of usinng the same

Country Status (13)

Country Link
EP (1) EP1917034A4 (en)
JP (1) JP2009504193A (en)
CN (1) CN101242855A (en)
AU (1) AU2005335743A1 (en)
BR (1) BRPI0520509A2 (en)
CA (1) CA2615761A1 (en)
EA (1) EA020130B9 (en)
EC (1) ECSP088241A (en)
HK (1) HK1211965A1 (en)
IL (2) IL189628A0 (en)
MX (1) MX2008002607A (en)
NO (1) NO20080893L (en)
WO (1) WO2007024222A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
US9844607B2 (en) 2013-02-05 2017-12-19 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
RU2015137856A (en) * 2013-02-05 2017-03-13 Санофи IMMUNOLOGICAL VISUALIZING AGENT FOR USE IN ANTI-MEDICINE CONJUGATE TREATMENT
WO2014122529A1 (en) * 2013-02-05 2014-08-14 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
US9989524B2 (en) 2013-02-05 2018-06-05 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
US20160347856A1 (en) * 2013-08-02 2016-12-01 Sanofi Use of Anti-MUC1 Maytansinoid Immunoconjugate Antibody for the Treatment of Solid Tumors
EP3188761A4 (en) 2014-09-02 2018-04-18 ImmunoGen, Inc. Methods for formulating antibody drug conjugate compositions
CN116514903A (en) 2014-09-03 2023-08-01 伊缪诺金公司 Cytotoxic benzodiazepine derivatives
US9381256B2 (en) 2014-09-03 2016-07-05 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
US20170189548A1 (en) 2015-11-25 2017-07-06 Immunogen, Inc. Pharmaceutical formulations and methods of use thereof
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
RU2765098C2 (en) 2017-02-28 2022-01-25 Иммуноджен, Инк. Maitanzinoid derivatives with self-splitting peptide linkers and their conjugates
US20180346488A1 (en) 2017-04-20 2018-12-06 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
EP3732178A1 (en) 2017-12-28 2020-11-04 ImmunoGen, Inc. Benzodiazepine derivatives
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596503B1 (en) * 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
BRPI0410260A (en) * 2003-05-14 2006-05-16 Immunogen Inc drug conjugate composition
BRPI0412879A8 (en) * 2003-07-21 2015-12-15 Immunogen Inc CA6 ANTIGEN SPECIFIC CYTOTOXIC CONJUGATE AND METHODS OF ITS USE

Also Published As

Publication number Publication date
NO20080893L (en) 2008-05-22
WO2007024222A1 (en) 2007-03-01
AU2005335743A1 (en) 2007-03-01
HK1211965A1 (en) 2016-06-03
CA2615761A1 (en) 2007-03-01
IL238798A0 (en) 2015-06-30
CN101242855A (en) 2008-08-13
BRPI0520509A2 (en) 2009-05-12
EA020130B9 (en) 2014-10-30
EP1917034A1 (en) 2008-05-07
MX2008002607A (en) 2008-03-19
JP2009504193A (en) 2009-02-05
EP1917034A4 (en) 2009-04-29
EA020130B1 (en) 2014-08-29
EA200800642A1 (en) 2008-08-29
ECSP088241A (en) 2008-04-28

Similar Documents

Publication Publication Date Title
IL189628A0 (en) An anti-ca6 monoclonal antibody and a ca6 antigen specific cytotoxic conjugate containing the same
IL272883A (en) Monoclonal antibodies and uses thereof
IL179672A (en) Human monoclonal anti-cd3 antibodies
EP1940466A4 (en) Anti-addl monoclonal antibody and use thereof
IL187710A0 (en) Anti-trkb monoclonal antibodies and uses thereof
ZA200607705B (en) Antibody calicheamicin conjugates
IL176755A0 (en) M-csf-specific monoclonal antibody and uses thereof
HK1098825A1 (en) Human monoclonal antibodies against cd20
IL206709A0 (en) Il-31 monoclonal antibodies
IL190502A0 (en) Anti-addl monoclonal antibody and use thereof
HK1111177A1 (en) M-csf specific monoclonal antibody and uses thereof m-csf
EP1717250A4 (en) Monoclonal antibody and use thereof
ZA200802051B (en) Anti-CD3 antibody formulations
WO2006031653A3 (en) Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates
EP1658095A4 (en) De-immunized anti-cd3 antibody
IL180152A0 (en) Chimeric and humanised monoclonal antibodies against inteleukin-13
PT2476705E (en) Monoclonal antibodies against nkg2a
IL185781A0 (en) Antibodies against candida antigens
EP2077325A4 (en) Monoclonal antibody and use thereof
EP2149582A4 (en) Osteopontin functional epitopes, monoclonal antibodies against the epitopes and uses thereof
HK1115598A1 (en) Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
HK1100848A1 (en) Anti-human tenascin monoclonal antibody
ZA200706185B (en) Monoclonal antibodies against NKG2A
EP1712564A4 (en) Anti-nc1 monoclonal antibody
ZA200800047B (en) Humanised antibodies specific for NOGO-A and pharmaceutical uses thereof